Description
Alceran (Melfalan) Powder for Solution for Injections 50 mg. №1 Vial
Ingredients
Active ingredient: Melfalan. Inactive ingredients may include mannitol and citric acid.
Mechanism of Action
Melfalan, an alkylating agent, exerts its pharmacological effects by damaging the DNA of cancer cells, thereby impeding their ability to replicate. This mechanism of action leads to the inhibition of cancer cell growth and proliferation within the body.
Pharmacological Properties
Melfalan, the active component of Alceran, belongs to the alkylating agent class of chemotherapy drugs. By interfering with the DNA of cancer cells, melfalan disrupts their ability to divide and multiply, ultimately hindering tumor progression.
Indications for Use
Indications: Alceran (Melfalan) is indicated for the treatment of multiple myeloma and ovarian cancer. It functions by impeding the growth or halting the proliferation of cancerous cells.
Contraindications
Contraindications: Avoid using Alceran (Melfalan) if there is a known hypersensitivity to melfalan or any of its inactive ingredients. Prior to use, disclose all existing medical conditions and ongoing medications to your healthcare provider.
Side Effects
Common side effects associated with Alceran (Melfalan) may include nausea, vomiting, bone marrow suppression, and increased susceptibility to infections. Contact your healthcare provider if any adverse reactions occur.
Usage Instructions
Dosage: The dosage of Alceran (Melfalan) is individualized by a healthcare professional and is typically administered intravenously. Refrain from self-administration and strictly follow medical guidance.
Benefits Compared to Analogues
Alceran (Melfalan) offers a distinct advantage over analogues due to its proven efficacy in treating multiple myeloma and ovarian cancer. Its targeted mechanism of action and well-established safety profile make it a preferred choice for oncologists.
Suitable Patient Groups
Alceran (Melfalan) is suitable for adult patients diagnosed with multiple myeloma or ovarian cancer. Dosage adjustments may be necessary for elderly individuals or those with compromised renal or hepatic function. Pediatric use should be determined by a pediatric oncology specialist.
Storage and Shelf Life
Store Alceran (Melfalan) as per the manufacturer’s instructions, typically at controlled room temperature. Check the expiry date on the packaging and do not use expired vials. Proper storage ensures the medication’s stability and efficacy.
Packaging Description
Alceran (Melfalan) is supplied in single-dose vials containing 50 mg of the active ingredient. The packaging is designed to maintain sterility and protect the product from external contaminants until use.
Clinical Evidence and Proven Effectiveness
Clinical Evidence: Studies have affirmed the therapeutic efficacy of Melfalan in managing multiple myeloma and ovarian cancer. Notably, research featured in the Journal of Clinical Oncology showcased the positive outcomes of Melfalan in combination therapy for multiple myeloma patients.
